Remove 2016 Remove FDA Remove Fraud Remove Governance
article thumbnail

Preventing Genetic Testing Fraud: 5 Actions for Health Plans

Healthcare IT Today

The following is a guest article by Erin Rutzler, Vice President of Fraud, Waste, and Abuse at Cotiviti In Delaware, more than 250 Medicare patients underwent unnecessary genetic testing based on telehealth consultations that often lasted less than two minutes— costing Medicare thousands of dollars per patient. In 2021, a U.S.

Fraud 62
article thumbnail

Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA

Bill of Health

In the July 29, 2022 notice, the USPTO set forth its views on the “duty of disclosure” and “duty of reasonable inquiry,” emphasizing the importance of consistency between statements made to the USPTO, the FDA, and other governmental agencies. MPEP § 2016. Background Context. The Duty of Reasonable Inquiry.

FDA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Health Provider News

Hall Render

Jill Biden will lead new initiative to boost federal government research into women’s health Joint Commission says acute, critical access hospitals must join safety network Lawsuit claims UnitedHealth AI wrongfully denies elderly extended care Most Rural U.S. Compensation is key Is spine surgery expansion next for ASCs? Many more are waiting.

article thumbnail

Health Provider News – February 10, 2023

Hall Render

Dunleavy proposes extending Medicaid coverage for new mothers ARIZONA Banner Health pays $1.25M penalty over HIPAA failures from 2016 breach Arizona nursing school at risk of losing accreditation St. billion since pandemic U.S. million to UMass Memorial Health Care for COVID-19 costs Four Mass.

article thumbnail

Reading Tea Leaves: Judge Brown Jackson’s Decisions Relevant To Product Liability

Drug & Device Law

have dockets heavy on administrative cases and other cases involving the functioning of the federal government and light on product liability cases. The MDL was established in June 2016. With more than eight years on the federal bench, that is not many decisions. Part of that may be that the D.D.C. Even the D.C. The first is pace.

FDA 59
article thumbnail

Suing the Certifiers – A Dangerous Undertaking

Drug & Device Law

The unfortunate truth is that ECFMG was also a victim of this fake doctor’s fraud. Furthermore, trade associations often serve to assist the government in areas that it does not regulate. 2016) (association’s “adoption of rules, policies, and procedures. . . Such power rests solely with the FDA.” at 183 (quoting Meyers v.

Doctors 52
article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

2023) (federal government may unilaterally obtain dismissal of FCA claims, and calling the constitutionality of the FCA’s private enforcement mechanism into question) ( here ); Quishenberry v. 2023) ( Buckman preemption barred MDL asserting fraud on EPA), cert. The FDA’s five reviews of teratogenic risk all came to the same conclusion.

FDA 105